Microglia, the resident immune cells of the central nervous system, play a crucial role in maintaining brain homeostasis. However, their dysregulation is a hallmark of neurodegenerative diseases. In Alzheimer’s disease, microglia can exhibit a pro-inflammatory M1 phenotype, which has been associated with increased neuroinflammation and consequent neuronal damage. The study by Wang et al. investigates how miR-199a-3p contributes to this pathogenic process by promoting or exacerbating M1 polarization of microglia.

The background of this research is rooted in the increasing recognition of the importance of non-coding RNAs, particularly microRNAs, in regulating gene expression and cellular processes. MicroRNAs are short, single-stranded RNA molecules that can modulate mRNA stability and translation. Dysregulation of specific microRNAs has been implicated in various diseases, including cancer and neurodegenerative disorders. In the context of Alzheimer’s disease, this regulatory aspect takes on heightened relevance as it might reveal novel therapeutic targets.

The study utilized a transgenic mouse model that expresses specific mutations in genes associated with familial Alzheimer’s disease. Researchers observed that these mice exhibited typical hallmarks of Alzheimer’s, including amyloid-beta plaque accumulation and neuroinflammation. Investigating the role of miR-199a-3p, they employed various techniques, including brain tissue analysis and flow cytometry, to examine microglial behavior and gene expression changes.

One of the significant findings of the research is the upregulation of miR-199a-3p in the brains of Alzheimer’s model mice. This increase correlated with enhanced levels of pro-inflammatory cytokines, suggesting a direct link between miR-199a-3p expression and neuroinflammatory processes. When the researchers explored the effect of inhibiting miR-199a-3p, they discovered a downregulation of M1 markers in microglia, indicating that this microRNA plays a pivotal role in promoting the pro-inflammatory state characteristic of Alzheimer’s pathology.

Further analysis revealed that miR-199a-3p targets specific messenger RNAs that encode proteins involved in anti-inflammatory signaling pathways. By downregulating these targets, miR-199a-3p effectively shifts the balance toward M1 polarization, instigating a cascade of inflammatory responses. This mechanism reinforces the idea that targeting microRNAs could be a promising therapeutic approach to mitigate neuroinflammation in Alzheimer’s disease.

The implications of these findings are profound. They suggest that therapies aimed at modulating miR-199a-3p levels could potentially reverse or alleviate neuroinflammatory conditions associated with Alzheimer’s disease. While pharmaceutical interventions are currently limited in their effectiveness against this devastating condition, the targeting of microRNAs offers a new horizon for therapeutic strategies.

Moreover, the study emphasizes the importance of understanding the multifactorial nature of Alzheimer’s disease pathology. Neuroinflammation does not act in isolation; it interacts with other molecular pathways, including amyloid-beta toxicity and tau pathology. The intricate interplay between these processes necessitates a comprehensive approach to treatment that considers the multifaceted underpinnings of the disease.

As the field moves forward, more research is needed to dissect the specific pathways through which miR-199a-3p mediates its effects on microglial polarization and neuroinflammation. Additionally, it will be crucial to explore how other microRNAs may contribute or counteract the effects of miR-199a-3p, providing a broader understanding of microRNA networks in the brain during Alzheimer’s disease.

In conclusion, the work of Wang and colleagues underpins a growing body of evidence demonstrating the critical roles that microRNAs play in neurodegenerative processes. Their findings not only enhance our understanding of the molecular mechanisms driving Alzheimer’s disease but also lay the groundwork for future innovations in therapeutics aimed at neuroinflammation. As researchers continue to unravel the complex tapestry of Alzheimer’s disease pathology, the potential for transformative treatments based on microRNA modulation becomes increasingly tangible.

In summary, the paper presents a compelling case for the involvement of miR-199a-3p in exacerbating neuroinflammation through M1 microglial polarization in Alzheimer’s disease models. This research not only enriches the scientific discourse surrounding Alzheimer’s but also serves as a clarion call for further investigations into the therapeutic potential of microRNA-based strategies.

Subject of Research: The role of MicroRNA-199a-3p in neuroinflammation and microglial polarization in Alzheimer’s disease.

Article Title: Publisher Correction: Mir-199a-3p aggravates neuroinflammation in an Alzheimer’s disease transgenic mouse model by promoting M1-polarization microglia.

Article References:

Wang, C., Bu, X., Cao, M. et al. Publisher Correction: Mir-199a-3p aggravates neuroinflammation in an Alzheimer’s disease transgenic mouse model by promoting M1-polarization microglia.
BMC Neurosci 26, 58 (2025). https://doi.org/10.1186/s12868-025-00974-4

Image Credits: AI Generated

DOI: 10.1186/s12868-025-00974-4

Keywords: Alzheimer’s disease, microRNA-199a-3p, neuroinflammation, microglia, M1 polarization, transgenic mouse model.

Microglia have long been recognized for their dual roles in maintaining homeostasis and responding to injury or disease in the CNS. These glial cells continuously survey the environment, clearing debris and dead cells, shaping synapses, and secreting signaling molecules that influence neuronal function. Upon aging, however, microglia undergo a transformation into a state often described as “primed” or “dysfunctional,” characterized by altered gene expression profiles and heightened inflammatory activity. Monteiro and Miron’s work sheds new light on how these aging microglia assume a central role in instigating and propagating white matter damage, not merely through autonomous activation but by actively recruiting peripheral immune cells into the brain.

At the heart of their findings is the identification of specific signaling pathways whereby aged microglia initiate chemokine and cytokine cascades that create a beacon for circulating T cells. Unlike the historically accepted view of the CNS as an immune-privileged sanctuary with limited interaction between CNS-resident immune cells and peripheral immune populations, this research demonstrates a nuanced breach